BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/7/2021 9:47:04 AM | Browse: 670 | Download: 1915
 |
Received |
|
2020-09-21 03:48 |
|
Peer-Review Started |
|
2020-09-21 03:49 |
|
First Decision by Editorial Office Director |
|
2020-11-16 22:01 |
|
Return for Revision |
|
2020-11-16 22:01 |
|
Revised |
|
2020-11-22 08:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-30 09:17 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-12-02 17:44 |
|
Articles in Press |
|
2020-12-02 17:44 |
|
Edit the Manuscript by Language Editor |
|
2020-12-11 13:06 |
|
Typeset the Manuscript |
|
2021-01-06 02:19 |
|
Publish the Manuscript Online |
|
2021-01-07 08:35 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Novel glucose-lowering drugs for non-alcoholic fatty liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zuo-Di Fu, Xiao-Ling Cai, Wen-Jia Yang, Ming-Ming Zhao, Ran Li and Yu-Feng Li |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Capital's Funds for Health Improvement and Research |
CFH2020-2-7131 |
|
| Corresponding Author |
Yu-Feng Li, MD, Chief Doctor, Department of Endocrinology, Beijing Friendship Hospital Pinggu Campus, Captital Medical University, 59 North Xinping Road, Beijing 101200, China. yflee@bjmu.edu.cn |
| Key Words |
Non-alcoholic fatty liver disease; Glucose-lowering drug; Meta-analysis; Dipeptidyl peptidase-4 inhibitor; Sodium-glucose cotransporter 2 inhibitor; Glucagon-like peptide-1 receptor agonist |
| Core Tip |
The efficacy of novel glucose-lowering drugs in treating non-alcoholic fatty liver disease is unknown. The results of this meta-analysis showed that treatment with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors demonstrated improvements in serum alanine aminotransferase and aspartate aminotransferase levels, indicating beneficial effect on the improvement of liver injury. |
| Publish Date |
2021-01-07 08:35 |
| Citation |
Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97
|
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i1/84.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i1.84 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
